Tokyo, Nov. 20 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059669) titled 'Effects of Mavacamten on Coronary Microcirculation in Obstructive Hypertrophic Cardiomyopathy' on Nov. 20.

Study Type: Observational

Primary Sponsor: Institute - KINDAI University

Condition: Condition - Obstructive Hypertrophic Cardiomyopathy Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - To elucidate the effects of mavacamten on coronary microcirculation in patients with symptomatic obstructive hypertrophic cardiomyopathy. Basic objectives2 - Efficacy

Eligibility: Age-lower limit - 18 years-old = Gender - Male and Female Key inclusion criteria - Patients diagnosed with obstructive hypertrophic cardiomyopathy (HCM)

Patients who meet the mavacamten administration criteria described in the 2025 revised Japanese Heart Failure Guidelines (those who continue to have NYHA functional class II-III symptoms despite pharmacological therapy with beta-blockers or calcium channel blockers)

Patients with a left ventricular ejection fraction (LVEF) >=55% at rest

Patients with a peak left ventricular outflow tract (LVOT) pressure gradient >=50 mmHg at rest, during Valsalva maneuver, or during exercise

Patients who have received a sufficient explanation regarding the purpose and details of this study, have fully understood it, and have provided written informed consent of their own free will Key exclusion criteria - Patients with a history of resuscitation after cardiac arrest

Patients with a history of syncope, sustained ventricular tachycardia, or appropriate implantable cardioverter-defibrillator (ICD) intervention within the past 6 months

Patients who have undergone surgical septal myectomy or percutaneous transluminal septal myocardial ablation (PTSMA) within the past 6 months

Patients with a history of hypersensitivity to mavacamten, severe hepatic impairment (Child-Pugh class C), or who are pregnant or possibly pregnant

Patients who refuse to participate in the study or are deemed ineligible by the principal investigator Target Size - 20

Recruitment Status: Recruitment status - Preinitiation Date of protocol fixation - 2025 Year 11 Month 11 Day Anticipated trial start date - 2025 Year 11 Month 20 Day Last follow-up date - 2029 Year 03 Month 31 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068255

Disclaimer: Curated by HT Syndication.